1991
DOI: 10.1111/j.1365-2125.1991.tb05543.x
|View full text |Cite
|
Sign up to set email alerts
|

The effects of diltiazem on hepatic drug metabolizing enzymes in man using antipyrine, trimethadione and debrisoquine as model substrates.

Abstract: Six healthy male subjects were given single oral doses of antipyrine (7 mg kg-'), trimethadione (4 mg kg-') and debrisoquine (10 mg) before and during diltiazem treatment (30 mg three times daily orally for 8 days). Antipyrine clearance decreased from 33.7 ± 9.1 to 22.5 ± 4.9 ml min-1 (P < 0.05, mean ± s.e. mean) after diltiazem treatment without any significant change in apparent volume of distribution (0.59 ± 0.06 to 0.60 ± 0.04 1 kg-1), resulting in an increase in antipyrine elimination half-life from 13.4 … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

1991
1991
2016
2016

Publication Types

Select...
3
2

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(1 citation statement)
references
References 24 publications
0
1
0
Order By: Relevance
“…Diltiazem is extensively metabolized in the liver into its host metabolites, primarily by deacetylation and demethylation by CYP3A4 in vitro and in vivo (Chaffman and Brogden, 1985;Pichard et al, 1990;Sutton et al, 1997;Jones et al, 1999;Nakagawa and Ishizaki, 2000;Yeo and Yeo, 2001;Kosuge et al, 2001), and probably in part by CYP2C8/9 (Sutton et al, 1997). In addition, diltiazem has been shown to increase the metabolic ratio of debrisoquine (Sakai et al, 1991), suggesting a possible interference with CYP2D6 (Molden et al, 2002). It is possible that the relevant enzyme activity to metabolize diltiazem or its metabolite(s) might be induced by themselves.…”
Section: Discussionmentioning
confidence: 97%
“…Diltiazem is extensively metabolized in the liver into its host metabolites, primarily by deacetylation and demethylation by CYP3A4 in vitro and in vivo (Chaffman and Brogden, 1985;Pichard et al, 1990;Sutton et al, 1997;Jones et al, 1999;Nakagawa and Ishizaki, 2000;Yeo and Yeo, 2001;Kosuge et al, 2001), and probably in part by CYP2C8/9 (Sutton et al, 1997). In addition, diltiazem has been shown to increase the metabolic ratio of debrisoquine (Sakai et al, 1991), suggesting a possible interference with CYP2D6 (Molden et al, 2002). It is possible that the relevant enzyme activity to metabolize diltiazem or its metabolite(s) might be induced by themselves.…”
Section: Discussionmentioning
confidence: 97%